Papillary carcinoma of thyroglossal cyst

Banerjee, Pranabashish; Ray, L I; Ray, Sanjay; Das, Somak; Sinha, Ramanuj

doi:10.1007/s12070-007-0107-1

Cited by 2 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ninety‐eight articles met the inclusion criteria and were included in the final analysis with a total population of 164 patients. Eighty‐one case reports and 17 case series were included 4–101 . The largest case series included 18 patients, and the studies that we evaluated spanned from 1986 to 2016.…”

Section: Resultsmentioning

confidence: 99%

Thyroglossal Duct Cyst Carcinoma: A Systematic Review of Clinical Features and Outcomes

Rayess

Monk

Svider

et al. 2017

Otolaryngol.--head neck surg.

115

View full text Add to dashboard Cite

Objective Although thyroglossal duct cysts (TGDCs) are relatively common, malignancies within these lesions are infrequent. As a result, there are no large-scale series describing clinical characteristics. Our objectives were to perform a systematic review of the literature evaluating patient demographics, pathology, management, and prognosis of these patients. Data Sources PubMed, Embase, Cochrane reviews, and Google Scholar were searched for relevant articles. Articles meeting inclusion criteria were reviewed for data detailing epidemiology, treatment, and outcomes. Review Methods Inclusion criteria included English-language articles with original reports on human subjects. Two investigators independently reviewed all articles for the data collected, including epidemiology, treatment, and outcomes. Results Ninety-eight articles comprising 164 patients were included in the final analysis. The mean age at presentation was 39.5 years (9-83 years); 68.3% of patients were female. In total, 73.3% of cases were found on final pathologic analysis. The most common pathology was papillary cancer (92.1%). Of the patients, 98.9% underwent a Sistrunk procedure and 61.0% underwent total thyroidectomy. There was a 4.3% recurrence rate with a mean time to recurrence of 42.1 months from initial treatment. One patient died of TGDC carcinoma, while all other patients were disease free at the time of last follow-up (mean follow-up was 46.1 months). Conclusion TGDC carcinoma is typically diagnosed on final pathology. While management encompasses a Sistrunk procedure, further consideration should be given to thyroidectomy among patients ≥45 years of age and individuals with aggressive disease. TGDC carcinoma harbors an exceedingly low rate of mortality.

show abstract

Section: Resultsmentioning

confidence: 99%

Thyroglossal Duct Cyst Carcinoma: A Systematic Review of Clinical Features and Outcomes

Rayess

Monk

Svider

et al. 2017

Otolaryngol.--head neck surg.

115

View full text Add to dashboard Cite

show abstract

“…Accumulating evidence has confirmed that the dysregulation of the MMPs/TIMPs signaling pathway was closely correlated to fibrosis and inflammation. [ 24,25 ] As described in Figure 3A, compared with the control group, the protein levels of MMPs, including MMP‐1, MMP‐2, MMP‐3, MMP‐9, MMP‐13, and MMP‐19 in BEAS‐2B cells were generally increased after CSE treatment. However, the increased MMPs were further decreased in different degrees by PPI treatment, especially on MMP‐9 expression.…”

Section: Resultsmentioning

confidence: 96%

Pacenta polypeptide injection alleviates the fibrosis and inflammation in cigarette smoke extracts‐induced BEAS‐2B cells by modulating MMP‐9/TIMP‐1 signaling

Zhu

et al. 2023

J Biochem & Molecular Tox

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) has high morbidity and mortality. Here, we aimed to explore the roles and potential correlation of placenta polypeptide injection (PPI) and MMP‐9/TIMP‐1 signaling pathway in COPD. BEAS‐2B cells were treated with cigarette smoke extract (CSE) to establish a COPD cell model in vitro. The cell survival and cytotoxic effect were measured by CCK‐8, LDH release and flow cytometry assays. The inflammatory responses were determined by western blot and ELISA assay. Cell fibrosis was assessed by immunofluorescence and western blot assays. PPI treatment had no cytotoxic effect on BEAS‐2B cells until the final concentration reached to 10%. In the range of 0%–8% final concentration, PPI treatment weakened CSE‐induced the decrease of cell viability and the increase of LDH level in a concentration‐dependent manner. Four percent PPI treatment enhanced cell viability and decreased cell apoptosis of CSE‐treated cells in a time‐dependent manner. Moreover, 4% PPI treatment significantly decreased inflammatory responses and fibrosis induced by CSE, while AMPA (MMPs agonist) had opposite effects. Notably, AMPA reversed the protective roles of PPI on CSE‐induced inflammation and fibrosis. Mechanistically, 4% PPI treatment significantly suppressed MMP‐1, MMP‐2, MMP‐3, MMP‐9, MMP‐13, and MMP‐19 levels, but enhanced TIMP‐1, TIMP‐2, TIMP‐3, and TIMP‐4 levels. Among them, MMP‐9 and TIMP‐1 might be the main target of PPI. PPI effectively attenuated CSE‐induced inflammation and fibrosis in vitro by regulating MMP‐9/TIMP‐1 signaling pathway.

show abstract

Papillary carcinoma of thyroglossal cyst

Cited by 2 publications

References 5 publications

Thyroglossal Duct Cyst Carcinoma: A Systematic Review of Clinical Features and Outcomes

Thyroglossal Duct Cyst Carcinoma: A Systematic Review of Clinical Features and Outcomes

Pacenta polypeptide injection alleviates the fibrosis and inflammation in cigarette smoke extracts‐induced BEAS‐2B cells by modulating MMP‐9/TIMP‐1 signaling

Contact Info

Product

Resources

About